To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
I2BC researchers, in collaboration with the European Institute of Chemistry and Biology (University of Bordeaux, CNRS), have developed a chimeric peptide/foldamer molecule that is resistant to proteolysis and inhibits ASF1, a potential target for anticancer treatment. The resolution of the structure of this chimera in interaction with its target, the first of its kind, reveals an unsuspected plasticity of the urea-based backbone that hugs the surface of ASF1.
SPI (DMTS), in collaboration with ANSES, has developed a test based on immuno-capture and targeted mass spectrometry for the quantitative and multiplex identification, in dairy products, of the eight main enterotoxins of Staphylococcus aureus, responsible for food poisoning epidemics.
I2BC researchers, in collaboration with the Autonomous University of Barcelona, have provided the first studies of the function and structural organization of a flippase encoded by a parasite responsible for malaria, a first step towards understanding the essential physiological function of this transporter and its potential use as an antimalarial target.
Le LEMM, en collaboration avec le LI2D et l’AP-HP, développe un test de diagnostic spécifique de la Covid-19 par spectrométrie de masse qui permettrait aussi la quantification de la charge virale du patient. Objectif à terme : adapter la méthode pour la rendre plus sensible et compatible avec les équipements d’analyse des hôpitaux.
By combining molecular dynamics and in vitro experiments, researchers at the LPSM (I2BC) have revealed the mode of action of sarcolipin in regulating the activity of SERCA1a, responsible for muscle relaxation.
A SCBM (DMTS) team, in collaboration with researchers at NeuroSpin and I2BC, is describing micellar nanometric vectors targeting tumors that have been imaged by fluorine magnetic resonance imaging (MRI). The observed 19F signal made it possible to precisely delimit the volume of the tumor zone in a mouse model and to quantify the probe accumulated in the target tissue.
Researchers from the LMC (DMTS), in collaboration with a team from AstraZeneca, have developed a labeling method, based on the exchange of carbon dioxide, simply using visible blue light and a photocatalyst.
The TIRO team (SHFJ), in collaboration with the neurovascular clinicians of the Nice and Marseille University Hospitals, carried out analyses of the metabolome of cerebral clots at the origin of the occlusion of a cerebral artery responsible for a cerebral vascular accident (stroke). A pilot study that improved the understanding of the complex relationship between blood glucose levels and patients' functional prognosis.
A study led by Oxford University researchers and involving researchers from the Institut Joliot (I2BC) and the University of Århus reveals the crucial role of the E340 residue in the inter-domain communication of the calcium transporter SERCA.
Researchers from I2BC and SPI (DMTS, Marcoule), in collaboration with CEA Grenoble and the Belgian nuclear research center, discovered, by using two meta-omic approaches, living bacteria in the core pool of the CEA Paris-Saclay research reactor, Osiris, in operation, thus opening up perspectives for the discovery of new radioresistant species.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.